Ulcerative colitis and Crohn’s disease are the two main types of inflammatory bowel disease (IBD), a group of conditions where the immune system mistakenly attacks the digestive tract. Together, they affect an estimated 2.4 to 3.1 million people in the United States alone. While they share many symptoms and even some treatments, they differ in where they strike, how deeply they damage tissue, and what complications they cause.
How They Differ
The simplest way to tell these two diseases apart is by location and depth. Ulcerative colitis only affects the large intestine (colon). It usually starts in the rectum and spreads upward in one continuous stretch with no gaps. The inflammation stays shallow, limited to the innermost lining of the colon wall.
Crohn’s disease can show up anywhere along the digestive tract, from the mouth to the anus, though it most commonly targets the end of the small intestine and the beginning of the colon. Unlike ulcerative colitis, Crohn’s often skips areas, leaving patches of healthy tissue between inflamed spots. It also burrows deeper, penetrating through multiple layers of the intestinal wall. This deeper inflammation is what drives many of the complications unique to Crohn’s.
What Causes IBD
Neither disease has a single cause. The current understanding is that IBD develops when a genetically susceptible person’s immune system overreacts to normal gut bacteria. Instead of tolerating the trillions of microbes that naturally live in the intestines, certain immune cells launch a sustained inflammatory attack against the intestinal lining.
A key protein involved in recognizing bacteria, produced by the NOD2 gene, has been closely linked to Crohn’s disease. Variations in this gene appear in about 40 percent of all people with Crohn’s. These genetic changes seem to prevent the immune system from properly detecting and managing gut bacteria, allowing microbes to invade the intestinal wall and trigger chronic inflammation. This association is strongest in people of northern European descent and in Crohn’s that affects the lower small intestine and colon.
On the immune side, a signaling molecule called TNF-alpha plays a central role in driving inflammation in both diseases. Other immune signals, particularly IL-12 and IL-23, help fuel the process by activating aggressive immune cells while suppressing the regulatory cells that would normally keep inflammation in check. These specific pathways have become the primary targets for modern treatments.
Common Symptoms
Both conditions share a core set of symptoms: persistent diarrhea, abdominal pain and cramping, fatigue, and unintended weight loss. Bloody stool is especially common in ulcerative colitis because inflammation sits right at the surface of the colon lining. Crohn’s disease may also cause bloody stool, but it more often presents with pain concentrated in the lower right abdomen, along with nausea or reduced appetite.
Both diseases follow a relapsing-remitting pattern. You may feel completely fine for weeks or months during remission, then experience a flare where symptoms return with full force. The unpredictability of flares is one of the most disruptive aspects of living with IBD.
Effects Beyond the Gut
IBD is not purely a digestive disease. Inflammation can spill over into other parts of the body, producing what doctors call extraintestinal manifestations. These are surprisingly common and sometimes appear before any gut symptoms do.
- Eyes: A painful form of eye inflammation called anterior uveitis affects 5% to 12% of people with Crohn’s and 3.5% to 4% of people with ulcerative colitis.
- Joints: Inflammatory arthritis affecting the spine and pelvis (sacroiliitis) occurs in roughly 8% of IBD patients. Among people who experienced an extraintestinal symptom before their IBD diagnosis, nearly 40% had this type of spinal inflammation.
- Liver: A condition called primary sclerosing cholangitis, which damages the bile ducts, affects up to 5% of people with ulcerative colitis. It is rare in Crohn’s.
- Skin: Painful red nodules on the shins and deep skin ulcers can occur in both diseases during flares.
Complications Specific to Each Disease
Because Crohn’s disease penetrates the full thickness of the intestinal wall, it can cause complications that ulcerative colitis typically does not. Fistulas, which are abnormal tunnels that form between the intestine and nearby organs, skin, or other sections of bowel, are a hallmark of Crohn’s. Strictures, or narrowed sections of intestine caused by scar tissue, can also develop over time and may eventually require surgery to relieve blockages.
Ulcerative colitis carries its own serious risks. Because it involves the entire colon lining in a continuous pattern, it creates a larger surface area of chronic inflammation. This raises the long-term risk of colorectal cancer, particularly after eight or more years of disease. Guidelines recommend a surveillance colonoscopy at the eight-year mark to assess risk factors, with follow-up intervals tailored to the amount of inflammation found. People with primary sclerosing cholangitis should begin surveillance immediately, as their cancer risk is higher.
How IBD Is Diagnosed
Diagnosis typically starts with blood tests and a stool test. One of the most useful screening tools is fecal calprotectin, a protein that leaks into stool when the intestines are inflamed. A level below 50 micrograms per gram makes IBD unlikely, while a level above that threshold warrants further investigation. In children, a higher cutoff of 250 micrograms per gram combined with other blood markers raises diagnostic accuracy significantly.
A colonoscopy with tissue biopsies is the definitive step. It allows a gastroenterologist to see the pattern of inflammation directly: continuous involvement starting from the rectum suggests ulcerative colitis, while patchy inflammation with skip areas points toward Crohn’s. Imaging of the small intestine, usually with MRI or CT, helps identify Crohn’s involvement in areas a colonoscopy can’t reach. In about 10% to 15% of cases where inflammation is limited to the colon, it can be difficult to distinguish between the two diseases, and an initial diagnosis may be revised over time.
Treatment Options
Treatment for both diseases follows a similar ladder, starting with milder therapies and escalating based on severity. For mild ulcerative colitis, anti-inflammatory drugs related to aspirin (5-aminosalicylic acid compounds) often control symptoms effectively. These drugs are less useful in Crohn’s disease.
For moderate to severe disease, the treatment landscape has expanded dramatically. Biologic medications that block TNF-alpha have been a cornerstone of IBD treatment for over two decades, improving symptoms, promoting healing of the intestinal lining, and extending periods of remission. When TNF-blocking therapies don’t work, drugs targeting IL-12 and IL-23 offer an effective alternative, particularly in Crohn’s disease. Early research suggests that IL-23 blockade can help patients who have stopped responding to TNF-targeted treatment, likely because the disease shifts to rely on different inflammatory pathways over time.
A newer class of oral medications, JAK inhibitors, represents the first small-molecule drugs approved for IBD. These pills block signals inside immune cells that amplify inflammation. Tofacitinib and filgotinib are approved for ulcerative colitis, while upadacitinib is the only JAK inhibitor currently approved for both Crohn’s disease and ulcerative colitis. Several others remain in clinical trials.
Steroids like prednisone are still used to bring severe flares under control quickly, but they aren’t suitable for long-term use because of significant side effects including bone loss, weight gain, and increased infection risk. The goal of modern IBD management is to find a maintenance therapy that keeps inflammation suppressed without steroids.
Surgery
When medications can’t control symptoms or complications arise, surgery becomes an option. For ulcerative colitis, removing the colon is technically curative since the disease doesn’t affect other parts of the digestive tract. Most people who undergo this surgery have their small intestine connected to an internal pouch that functions in place of the colon, allowing them to have bowel movements without a permanent external bag.
Surgery for Crohn’s disease is more complicated because the disease can recur anywhere in the digestive tract. Operations typically focus on removing damaged sections, draining abscesses, or repairing fistulas. Roughly half of people with Crohn’s will need at least one surgery within the first ten years of diagnosis, and recurrence at or near the surgical site is common. For this reason, surgery in Crohn’s is considered a tool alongside medication rather than a cure.